PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

naproxen Side Effects

The reactions most often reported to the FDA for naproxen (also sold as Aleve, Naprosyn), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

75,912
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of naproxen come from 75,912 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 75,912 reports to the FDA Adverse Event Reporting System (FAERS) for naproxen (Aleve): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

75,912

Reports Mentioning Death

7,527

9.9% of reports — not proof the medicine caused the death

Hospitalizations

25,220

33.2% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

PAIN
8,756
FATIGUE
7,339
ARTHRALGIA
7,243
NAUSEA
7,062
HEADACHE
5,716
DIARRHOEA
5,350
VOMITING
4,746
DIZZINESS
4,711
RASH
4,612
DYSPNOEA
4,585
MALAISE
4,452
JOINT SWELLING
4,358
PAIN IN EXTREMITY
4,337
RHEUMATOID ARTHRITIS
4,309
CONDITION AGGRAVATED
3,652
BACK PAIN
3,307
MUSCULOSKELETAL STIFFNESS
3,289

Who Reports Side Effects

Gender Distribution

Female 46,198 (67%)
Male 22,842 (33%)
Unknown 156

Age Distribution

0-17 2,117 (4%)
18-44 14,973 (28%)
45-64 22,657 (43%)
65-74 8,184 (16%)
75+ 4,664 (9%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 7,527 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 1,314
COMPLETED SUICIDE 1,194
SYSTEMIC LUPUS ERYTHEMATOSUS 1,175
PAIN 1,166
RASH 1,152
SYNOVITIS 1,142
TYPE 2 DIABETES MELLITUS 1,142
SWELLING 1,089
PEMPHIGUS 1,084
WOUND 1,082
GENERAL PHYSICAL HEALTH DETERIORATION 1,076
GLOSSODYNIA 1,076
INFUSION RELATED REACTION 1,072
RHEUMATOID ARTHRITIS 1,071
PSORIATIC ARTHROPATHY 1,064
VOMITING 1,050
HYPOAESTHESIA 1,038
PERICARDITIS 1,038
FOLLICULITIS 1,017

Reactions in Hospitalization Reports

Top reactions in 25,220 reports where hospitalization was an outcome.

Reaction Reports
PAIN 3,636
NAUSEA 3,029
FATIGUE 2,923
ARTHRALGIA 2,751
VOMITING 2,736
DIARRHOEA 2,581
RASH 2,496
DYSPNOEA 2,305
HEADACHE 2,273
MALAISE 2,186
DIZZINESS 2,090
SYNOVITIS 2,084
RHEUMATOID ARTHRITIS 2,067
CONDITION AGGRAVATED 2,010
PAIN IN EXTREMITY 1,915
ARTHROPATHY 1,900
JOINT SWELLING 1,898
PNEUMONIA 1,854

Compare naproxen vs abatacept →

What the FAERS Data Reveals About naproxen Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 75,912 voluntary reports linked to naproxen and its brand equivalents (Aleve, Naprosyn), spanning 2004 through 2025. Of those, 7,527 (9.9%) listed death as an outcome and 25,220 (33.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 67% were female and 33% male; age distribution skews toward 45-64, with 22,657 reports in that bracket. The single most reported reaction is pain with 8,756 submissions, followed by fatigue and arthralgia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.